Locations:
Search IconSearch
October 18, 2023/Cancer/News & Insight

Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4274330-CQD-Hero-650×450

As new therapies and modalities are emerging for treating head and neck cancers, Cleveland Clinic Cancer Center is hosting an in-person CME program highlighting:

  • Emerging surgical techniques
  • Radiation and chemotherapy best practices
  • Recognizing and diagnosing rare head and neck cancers
  • The necessity for multidisciplinary care
  • Managing referral decisions

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The course will highlight innovative approaches to head and neck cancer treatment,” says Joseph Scharpf, MD, Director of Head and Neck Endocrine Surgery at Cleveland Clinic. “It will provide an excellent contemporary update and highlight cutting-edge treatments, which have evolved in all the specialties represented.”

The program, entitled 2023 Contemporary Multidisciplinary Care of the Head and Neck Cancer Patient: Updates on the Innovative Approaches to Head and Neck Cancer Treatment, will be held on Friday, November 17, 2023 at Cleveland Clinic Learner Research Institute. The sessions are recommended for head and neck surgeons, otolaryngologists, medical oncologists, radiation oncologists, trainees, advanced practice providers as well as speech language pathologists and nurses involved in the diagnosis and treatment of head and neck cancers.

Specialists from head and neck oncology, head and neck endocrine surgery, radiation oncology, medical oncology, speech and language pathology, oral rehabilitation surgery, dermatologic surgery, radiology, pathology and reconstructive surgery will lead the sessions. “The panels include expert faculty drawing from leaders in our field internally at Cleveland Clinic and nationally recognized guests, including an alumnus as a guest of honor,” says Dr. Scharpf.

Program highlights

Sessions will cover:

  • Advances in screening and prevention of head and neck cancer
  • Utilization of molecular and nonmolecular biomarkers in treatment decisions
  • Recent innovations in treating advanced cutaneous squamous cell carcinoma
  • Innovative approaches to improving functional and quality of life outcomes
  • Tumor board cases

Advertisement

CME credits

This live activity represents a maximum of 7.50 AM PRA category 1 credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for category 2 credit. A certificate of participation will be provided to other health care professionals for requesting credit in accordance with their professional boards and/or associations.

Session fee

$150 for physicians
$50 for allied health professionals, residents and fellows

Register now.

Advertisement

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023/Cancer/News & Insight
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023/Cancer/News & Insight
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

prostate cancer
Lutetium-PSMA for Metastatic Prostate Cancer (Podcast)

FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer

Ad